ArticleJournal of translational medicine2026
Dual-block HER2 assessment reveals clinically relevant intratumoral heterogeneity in gynecologic cancers: a single-center landscape analysis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundGynecologic cancers remain a substantial clinical challenge, particularly in advanced stages, where treatment options are often associated with limited efficacy and poor prognosis. Given the emerging success of HER2-targeted antibody-drug conjugates (ADCs) across solid tumors, accurate evaluation of HER2 status is essential. This study investigated intratumoral HER2 heterogeneity in gynecologic cancers to refine detection accuracy and improve patient stratification for targeted therapy.
methodsA retrospective cohort of 416 patients with gynecologic malignancies was analyzed using immunohistochemistry (IHC) testing on separate dual formalin-fixed paraffin-embedded (FFPE) tumor blocks. HER2 expression was scored according to ASCO/CAP gastric criteria, and heterogeneity was defined as discordant IHC scores across blocks. Statistical analyses were performed using McNemar's test, and clinical predictors of discordance were identified through multivariate logistic regression.
resultsAcross all tumors, HER2 IHC scores were distributed as 0 (49.5%), 1+ (33.9%), 2+ (15.6%), and 3+ (1.0%). HER2 overexpression was most frequent in uterine serous carcinoma, uterine endometrioid carcinoma, and ovarian clear cell carcinoma in our cohort. Intratumoral discordance was observed in 20.7% of cases, with the highest rates in uterine (23.9%, 21/88), ovarian (21.4%, 39/182), and cervical (18.2%, 26/143) tumors. Dual-block assessment revealed that most discrepancies resulted from incremental shifts in HER2 expression, primarily from 0 to 1 + or 1 + to 2+. This approach reclassified 13.5% of tumors originally reported as HER2-0 to HER2 expression.
conclusionIntratumoral HER2 heterogeneity is common in gynecologic cancers and frequently results in underestimation of HER2 expression when single-block assessment is used. Dual-block evaluation improves detection sensitivity and may refine patient selection for HER2-targeted antibody-drug conjugates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.